Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
If approved, DTX401 would be the first treatment to address the disease at its root cause
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Subscribe To Our Newsletter & Stay Updated